vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and Koppers Holdings Inc. (KOP). Click either name above to swap in a different company.
Koppers Holdings Inc. is the larger business by last-quarter revenue ($432.7M vs $346.4M, roughly 1.2× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 28.1% vs 6.9%, a 21.2% gap on every dollar of revenue. On growth, HAEMONETICS CORP posted the faster year-over-year revenue change (4.8% vs -9.3%). HAEMONETICS CORP produced more free cash flow last quarter ($209.9M vs $28.5M). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (1.5% CAGR vs -6.7%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Koppers is a global chemical and materials company based in Pittsburgh, Pennsylvania, United States. Its headquarters is an art-deco 1920s skyscraper, the Koppers Tower.
HAE vs KOP — Head-to-Head
Income Statement — Q4 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $346.4M | $432.7M |
| Net Profit | $97.3M | $29.7M |
| Gross Margin | 57.2% | 25.6% |
| Operating Margin | 36.1% | 11.5% |
| Net Margin | 28.1% | 6.9% |
| Revenue YoY | 4.8% | -9.3% |
| Net Profit YoY | — | 391.2% |
| EPS (diluted) | — | $1.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $346.4M | — | ||
| Q4 25 | $339.0M | $432.7M | ||
| Q3 25 | $327.3M | $485.3M | ||
| Q2 25 | $321.4M | $504.8M | ||
| Q1 25 | $330.6M | $456.5M | ||
| Q4 24 | $348.5M | $477.0M | ||
| Q3 24 | $345.5M | $554.3M | ||
| Q2 24 | $336.2M | $563.2M |
| Q1 26 | $97.3M | — | ||
| Q4 25 | $44.7M | $29.7M | ||
| Q3 25 | $38.7M | $23.8M | ||
| Q2 25 | $34.0M | $16.4M | ||
| Q1 25 | $58.0M | $-13.9M | ||
| Q4 24 | $37.5M | $-10.2M | ||
| Q3 24 | $33.8M | $22.8M | ||
| Q2 24 | $38.4M | $26.8M |
| Q1 26 | 57.2% | — | ||
| Q4 25 | 59.7% | 25.6% | ||
| Q3 25 | 59.5% | 24.1% | ||
| Q2 25 | 59.8% | 22.6% | ||
| Q1 25 | 58.4% | 23.2% | ||
| Q4 24 | 55.5% | 17.5% | ||
| Q3 24 | 54.2% | 21.9% | ||
| Q2 24 | 52.0% | 21.6% |
| Q1 26 | 36.1% | — | ||
| Q4 25 | 19.9% | 11.5% | ||
| Q3 25 | 17.9% | 10.7% | ||
| Q2 25 | 16.8% | 7.7% | ||
| Q1 25 | 21.6% | 5.9% | ||
| Q4 24 | 16.9% | 1.3% | ||
| Q3 24 | 15.0% | 9.0% | ||
| Q2 24 | 11.8% | 10.2% |
| Q1 26 | 28.1% | — | ||
| Q4 25 | 13.2% | 6.9% | ||
| Q3 25 | 11.8% | 4.9% | ||
| Q2 25 | 10.6% | 3.2% | ||
| Q1 25 | 17.5% | -3.0% | ||
| Q4 24 | 10.8% | -2.1% | ||
| Q3 24 | 9.8% | 4.1% | ||
| Q2 24 | 11.4% | 4.8% |
| Q1 26 | — | — | ||
| Q4 25 | $0.95 | $1.44 | ||
| Q3 25 | $0.81 | $1.17 | ||
| Q2 25 | $0.70 | $0.81 | ||
| Q1 25 | $1.17 | $-0.68 | ||
| Q4 24 | $0.74 | $-0.47 | ||
| Q3 24 | $0.66 | $1.09 | ||
| Q2 24 | $0.74 | $1.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $245.4M | — |
| Total DebtLower is stronger | $1.2B | $928.3M |
| Stockholders' EquityBook value | $796.3M | $574.0M |
| Total Assets | $2.4B | $1.9B |
| Debt / EquityLower = less leverage | 1.53× | 1.62× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $245.4M | — | ||
| Q4 25 | $363.4M | — | ||
| Q3 25 | $296.4M | — | ||
| Q2 25 | $292.9M | — | ||
| Q1 25 | $306.8M | — | ||
| Q4 24 | $320.8M | — | ||
| Q3 24 | $299.3M | — | ||
| Q2 24 | $344.4M | — |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $928.3M | ||
| Q3 25 | $1.2B | $932.9M | ||
| Q2 25 | $1.2B | $977.5M | ||
| Q1 25 | $1.2B | $989.0M | ||
| Q4 24 | — | $939.5M | ||
| Q3 24 | — | $989.4M | ||
| Q2 24 | — | $1.0B |
| Q1 26 | $796.3M | — | ||
| Q4 25 | $911.5M | $574.0M | ||
| Q3 25 | $849.2M | $545.6M | ||
| Q2 25 | $882.3M | $526.8M | ||
| Q1 25 | $820.8M | $498.0M | ||
| Q4 24 | $906.9M | $488.7M | ||
| Q3 24 | $878.9M | $532.3M | ||
| Q2 24 | $905.4M | $509.2M |
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.5B | $1.9B | ||
| Q3 25 | $2.4B | $1.9B | ||
| Q2 25 | $2.5B | $1.9B | ||
| Q1 25 | $2.5B | $1.9B | ||
| Q4 24 | $2.5B | $1.9B | ||
| Q3 24 | $2.5B | $2.0B | ||
| Q2 24 | $2.5B | $1.9B |
| Q1 26 | 1.53× | — | ||
| Q4 25 | 1.34× | 1.62× | ||
| Q3 25 | 1.44× | 1.71× | ||
| Q2 25 | 1.39× | 1.86× | ||
| Q1 25 | 1.49× | 1.99× | ||
| Q4 24 | — | 1.92× | ||
| Q3 24 | — | 1.86× | ||
| Q2 24 | — | 1.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $293.2M | $45.1M |
| Free Cash FlowOCF − Capex | $209.9M | $28.5M |
| FCF MarginFCF / Revenue | 60.6% | 6.6% |
| Capex IntensityCapex / Revenue | 9.5% | 3.8% |
| Cash ConversionOCF / Net Profit | 3.01× | 1.52× |
| TTM Free Cash FlowTrailing 4 quarters | $417.1M | $67.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $293.2M | — | ||
| Q4 25 | $93.6M | $45.1M | ||
| Q3 25 | $111.3M | $49.6M | ||
| Q2 25 | $17.4M | $50.5M | ||
| Q1 25 | $116.6M | $-22.7M | ||
| Q4 24 | $43.8M | $74.7M | ||
| Q3 24 | $48.8M | $29.8M | ||
| Q2 24 | $-27.4M | $27.2M |
| Q1 26 | $209.9M | — | ||
| Q4 25 | $87.2M | $28.5M | ||
| Q3 25 | $106.3M | $37.6M | ||
| Q2 25 | $13.6M | $38.4M | ||
| Q1 25 | $100.9M | $-37.0M | ||
| Q4 24 | $35.2M | $56.1M | ||
| Q3 24 | $39.4M | $14.4M | ||
| Q2 24 | $-33.1M | $10.1M |
| Q1 26 | 60.6% | — | ||
| Q4 25 | 25.7% | 6.6% | ||
| Q3 25 | 32.5% | 7.7% | ||
| Q2 25 | 4.2% | 7.6% | ||
| Q1 25 | 30.5% | -8.1% | ||
| Q4 24 | 10.1% | 11.8% | ||
| Q3 24 | 11.4% | 2.6% | ||
| Q2 24 | -9.8% | 1.8% |
| Q1 26 | 9.5% | — | ||
| Q4 25 | 1.9% | 3.8% | ||
| Q3 25 | 1.5% | 2.5% | ||
| Q2 25 | 1.2% | 2.4% | ||
| Q1 25 | 4.7% | 3.1% | ||
| Q4 24 | 2.5% | 3.9% | ||
| Q3 24 | 2.7% | 2.8% | ||
| Q2 24 | 1.7% | 3.0% |
| Q1 26 | 3.01× | — | ||
| Q4 25 | 2.09× | 1.52× | ||
| Q3 25 | 2.88× | 2.08× | ||
| Q2 25 | 0.51× | 3.08× | ||
| Q1 25 | 2.01× | — | ||
| Q4 24 | 1.17× | — | ||
| Q3 24 | 1.44× | 1.31× | ||
| Q2 24 | -0.71× | 1.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
KOP
| Other | $127.8M | 30% |
| Railroad Treated Products | $119.0M | 28% |
| Utility Poles | $79.8M | 18% |
| Pitch And Related Products | $74.1M | 17% |
| Carbon Black Feedstock And Distillates | $14.4M | 3% |
| Railroad Infrastructure Products And Services | $9.9M | 2% |
| Phthalic Anhydride Naphthalene And Other Chemicals | $7.7M | 2% |
